Literature DB >> 16871523

Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs).

Henryk Mach1, David B Volkin, Robert D Troutman, Bei Wang, Zheng Luo, Kathrin U Jansen, Li Shi.   

Abstract

The human papillomavirus (HPV) virus-like particles (VLPs) produced by recombinant expression systems are promising candidate vaccine antigens for prevention of cervical cancers as well as genital warts. However, expression of HPV type 6, 11, and 16 L1 proteins in Saccharomyces cerevisiae yielded irregularly shaped, broadly distributed VLPs smaller in size (30-50 nm) than expected (60 nm). In this study, we demonstrate that these HPV VLPs can be disassembled into the constituent capsomers (L1 pentamers) by incubation at low ionic strength and elevated pH in the presence of relatively low concentration of reducing agents. Following the removal of reducing agents, lowering of pH and increasing of ionic strength, the capsomers spontaneously reassembled into homogenous, 60-nm VLPs characterized by significantly enhanced structural stability and improved immunogenicity. In order to achieve quantitative recovery of HPV VLPs, the disassembly/reassembly process was further optimized by use of high ionic strength (>0.5 M sodium chloride) to prevent aggregation of VLPs. The reassembled VLPs possess an architectural structure very similar to that of the natural HPV virus particles. This development illustrates how the natural, in vivo mechanisms facilitating cell entry and virus replication can be utilized to achieve an optimal, in vitro assembly state of yeast-expressed HPV VLPs. Copyright (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871523     DOI: 10.1002/jps.20696

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  27 in total

1.  Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle vaccine platform.

Authors:  John R Gallagher; Udana Torian; Dustin M McCraw; Audray K Harris
Journal:  Virology       Date:  2017-01-03       Impact factor: 3.616

2.  Multiplexed serologic assay for nine anogenital human papillomavirus types.

Authors:  David Opalka; Katie Matys; Paul Bojczuk; Tina Green; Richard Gesser; Alfred Saah; Richard Haupt; Frank Dutko; Mark T Esser
Journal:  Clin Vaccine Immunol       Date:  2010-03-17

3.  Two decades of publishing excellence in pharmaceutical biotechnology.

Authors:  David B Volkin; Susan Hershenson; Rodney J Y Ho; Susumu Uchiyama; Gerhard Winter; John F Carpenter
Journal:  J Pharm Sci       Date:  2014-12-01       Impact factor: 3.534

4.  Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

5.  Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy.

Authors:  Qinjian Zhao; Clinton S Potter; Bridget Carragher; Gabriel Lander; Jaime Sworen; Victoria Towne; Dicky Abraham; Paul Duncan; Michael W Washabaugh; Robert D Sitrin
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

6.  Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58.

Authors:  Martha J Brown; Hanna Seitz; Victoria Towne; Martin Müller; Adam C Finnefrock
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

Review 7.  Replication and assembly of human papillomaviruses.

Authors:  M J Conway; C Meyers
Journal:  J Dent Res       Date:  2009-04       Impact factor: 6.116

8.  Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris.

Authors:  Silvia Boschi Bazan; Agtha de Alencar Muniz Chaves; Karina Araújo Aires; Aurora Marques Cianciarullo; Robert L Garcea; Paulo Lee Ho
Journal:  Arch Virol       Date:  2009-09-10       Impact factor: 2.574

9.  Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines.

Authors:  Michael J Conway; Samina Alam; Neil D Christensen; Craig Meyers
Journal:  Virology       Date:  2009-09-05       Impact factor: 3.616

10.  A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging.

Authors:  Carla Cerqueira; Yuk-Ying S Pang; Patricia M Day; Cynthia D Thompson; Christopher B Buck; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.